NewGenIvf Group Limited (NASDAQ: NIVFW) operates as a fertility services provider offering comprehensive in vitro fertilization (IVF) treatments and related reproductive health solutions. The company delivers core services including IVF cycles, intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), embryo freezing and storage, egg donation programs, and surrogacy arrangements; it also provides ancillary offerings such as fertility consultations, andrological assessments, and advanced reproductive technologies through its network of clinics. Headquartered in Hong Kong and founded in 2018, NewGenIvf serves patients across Asia-Pacific markets including Hong Kong, mainland China, and Southeast Asia, targeting individuals and couples seeking assisted reproductive technologies. In recent developments within the last two years, the company has expanded its clinic footprint through strategic clinic openings in key urban centers and formed alliances with regional healthcare providers to enhance service accessibility; it completed a Nasdaq listing via a SPAC merger in 2023, securing funding for operational growth and technology upgrades in its laboratories.